Nobody's child

Berliner, Neil
November 2007
Pharmaceutical Representative;Nov2007, Vol. 37 Issue 11, p39
An interview with Paul Stickler is presented. When asked about how the representatives in their company differ from other traditional pharmaceutical, he commented that their representatives are very dedicated to patients with rare and complicated medical problems. Stickler stated that their representatives are looked for by physicians. He mentioned that acute intermittent porphyria is an example of a rare condition that is treated by one of their products.


Related Articles

  • Show me the money. Giles, Jim // New Scientist;2/21/2009, Vol. 201 Issue 2696, p26 

    An interview with U.S. Republican senator Chuck Grassley on his campaign to force doctors, researchers and drug companies to reveal their financial relationships. Asked if it matters that some academics and doctors forget to declare their income from drug companies, he answered that it really...

  • CORRUPTION IN THE PHARMACEUTICAL SECTOR. Riegl, Martin // New Presence: The Prague Journal of Central European Affairs;Autumn2008, Vol. 10 Issue 3, p18 

    An interview with Jan Hnizdil, who is fighting corruption of doctors by pharmaceutical companies, is presented. When asked whether speculation over corruption in the industry is an isolated case, in which an insurance company was supposed to sponsor a planned urological conference, he said it is...

  • WHY COMPOUNDED PRESCRIPTIONS MAKE SENSE: AN INTERVIEW WITH DAVID BROWNSTEIN, MD. Stewart, Kimberly Lord // Integrative Medicine: A Clinician's Journal;Oct/Nov2006, Vol. 5 Issue 5, p64 

    The article presents an interview with David Brwonstein, psychiatrist and practitioner of holistic medicine. When asked about the reason of using compounded prescriptions, he answers that it suits individual requirements, which pharmaceutical companies fail to cater. He reveals about the role of...

  • Blisters on her hands and excess hair on her face. Levine, Norman // Modern Medicine;May94, Vol. 62 Issue 5, p66 

    Presents a case of the disease porphyria cutanea tarda. Differential diagnosis; Symptoms; Treatment.

  • Top-notch science op. Rollins, Gina // Modern Physician;Sep2002, Vol. 6 Issue 9, p22 

    Discusses the rewards and opportunities provided by the pharmaceutical industry to physician executives in the U.S. Main appeals of the industry to physicians; Perception on the industry; Qualities and skills that are important to physician executives in the pharmaceutical industry.

  • Meet the EAB. Booth, Shannon // Applied Clinical Trials;Nov2003, Vol. 12 Issue 11, p40 

    No abstract available.

  • Dialysis: High Costs and Hidden Perils of a Treatment Guaranteed to All: Dialysis Data, Once Confidential, Shines Light on Clinic Disparities. Fields, Robin // Pro Publica;12/19/2010, p16 

    An introduction is presented which discusses several reports published within the journal on topics including steps taken by drug companies to retain control of physicians presentation, payments made to doctors and failure of Pentagon health plan in covering brain-damage therapy troops.

  • Drug Companies and Doctors: A Tight-Knit Community.  // People's Medical Society Newsletter;Jun2001, Vol. 20 Issue 3, p2 

    Deals with the influence that drug manufacturers have over the prescribing and professional behavior of physicians according to an article in the January 19, 2001 issue of the `Journal of the American Medical Association.'

  • Charging drug representatives for physician visits: Three leaders explain why and how.  // Formulary;Nov2002, Vol. 37 Issue 11, p594 

    Presents physicians' views about the charging of drug representatives for physician visits. Benefits to physicians of drug representative visits; Reasons for the implementation of fee-for-visit policy; Number of pharmaceutical firms that have agreed to the policy. INSETS: Facts at a glance:...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics